Junchun Chen

Shenzhen, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 17 publications

Correction: Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.

Correction: Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.

Journal: Cell death discovery

Published: March 30, 2026

Isoginkgetin Inhibits RANKL-induced Osteoclastogenesis and Alleviates Bone Loss.

Isoginkgetin Inhibits RANKL-induced Osteoclastogenesis and Alleviates Bone Loss.

Journal: Biochemical pharmacology

Published: August 29, 2024

Heme metabolism mediates RANKL-induced osteoclastogenesis via mitochondrial oxidative phosphorylation.

Heme metabolism mediates RANKL-induced osteoclastogenesis via mitochondrial oxidative phosphorylation.

Journal: Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research

Published: May 25, 2024

Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function.

Corylifol A suppresses osteoclastogenesis and alleviates ovariectomy-induced bone loss via attenuating ROS production and impairing mitochondrial function.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: October 30, 2023

Trifolirhizin reduces osteoclast formation and prevents inflammatory osteolysis by inhibiting RANKL-induced activation of NF-κB and MAPK signaling pathways and ROS.

Trifolirhizin reduces osteoclast formation and prevents inflammatory osteolysis by inhibiting RANKL-induced activation of NF-κB and MAPK signaling pathways and ROS.

Journal: Phytotherapy research : PTR

Published: October 18, 2023

Aminooxyacetic acid hemihydrochloride leads to decreased intracellular ATP levels and altered cell cycle of prostate cancer cells by suppressing energy metabolism.

Aminooxyacetic acid hemihydrochloride leads to decreased intracellular ATP levels and altered cell cycle of prostate cancer cells by suppressing energy metabolism.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 22, 2023

Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.

Periplogenin attenuates LPS-mediated inflammatory osteolysis through the suppression of osteoclastogenesis via reducing the NF-κB and MAPK signaling pathways.

Journal: Cell death discovery

Published: July 20, 2023

CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca2+ oscillations and NF-κB/MAPK signaling pathways.

CGK733 alleviates ovariectomy-induced bone loss through blocking RANKL-mediated Ca2+ oscillations and NF-κB/MAPK signaling pathways.

Journal: iScience

Published: May 11, 2023

IKK/NF-κB and ROS signal axes are involved in Tenacissoside H mediated inhibitory effects on LPS-induced inflammatory osteolysis.

IKK/NF-κB and ROS signal axes are involved in Tenacissoside H mediated inhibitory effects on LPS-induced inflammatory osteolysis.

Journal: Cell proliferation

Published: February 27, 2023

Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding.

Isoliensinine suppresses bone loss by targeted inhibition of RANKL-RANK binding.

Journal: Biochemical pharmacology

Published: January 23, 2023

Pteryxin suppresses osteoclastogenesis and prevents bone loss via inhibiting the MAPK/Ca2+ signaling pathways mediated by ROS.

Pteryxin suppresses osteoclastogenesis and prevents bone loss via inhibiting the MAPK/Ca2+ signaling pathways mediated by ROS.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: January 13, 2023

Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways.

Casticin suppresses RANKL‑induced osteoclastogenesis and prevents ovariectomy‑induced bone loss by regulating the AKT/ERK and NF‑κB signaling pathways.

Journal: International journal of molecular medicine

Published: November 17, 2022

Showing 1-12 of 17

Last Updated: 09/26/2026